Important: Selank's human anxiety data comes from Russian trials not yet independently replicated to Western regulatory standards.
Overview
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension that dramatically enhances metabolic stability. Selank has been approved in Russia and Ukraine as an anxiolytic and nootropic agent, with clinical use for generalized anxiety disorder, neurasthenia, and cognitive impairment. Unlike benzodiazepines, which act as positive allosteric modulators of GABA-A receptors and carry significant risks of dependence, tolerance, and cognitive impairment, selank is reported to exert anxiolytic effects through a more nuanced modulation of GABAergic, serotonergic, and dopaminergic systems without the sedative or dependence-producing properties of classical anxiolytics.
Mechanism of Action
Selank's mechanism of action involves multiple neurotransmitter systems. The primary anxiolytic mechanism appears to involve modulation of the GABAergic system: selank increases the expression of GABA-A receptor subunits and enhances GABAergic transmission without directly binding to the benzodiazepine site, potentially explaining its anxiolytic effects without the sedation and dependence associated with benzodiazepines. Selank also modulates the serotonergic system, increasing 5-HT turnover in the hippocampus and frontal cortex, and the dopaminergic system, with effects on dopamine metabolism in limbic structures. Additionally, selank upregulates brain-derived neurotrophic factor (BDNF) ex
Research Evidence
- Approved anxiolytic/nootropic in Russia and Ukraine for GAD and neurasthenia
- GABAergic modulation without benzodiazepine site binding — no dependence or sedation reported
- Increases BDNF expression in hippocampus and frontal cortex (nootropic mechanism)
- Modulates serotonin turnover in hippocampus and frontal cortex
- Immunomodulatory activity via tuftsin-derived mechanisms (T-cell modulation, IL-6, IFN-γ)
Bottom line: Selank is one of the most clinically used cognitive/anxiolytic peptides in this catalog, with approved clinical status in Russia. Its non-sedating, non-habit-forming profile makes it an interesting research subject for anxiety and cognitive biology. The majority of its evidence base is in the Russian literature, and independent Western replication is limited. Research-only compound.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Selank are detailed in the full compound profile. See also: Dosage guide for Selank.
Sourcing & Quality
Selank is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Selank at Purgo Labs.